Quick Answer
CytoDyn Inc. reported Cash and Equivalents of $11.90 million for fiscal year 2025.
CytoDyn Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $11.90M | +282.7% |
| 2024 | $3.11M | +22.4% |
| 2023 | $2.54M | -39.9% |
| 2022 | $4.23M | -87.5% |
| 2021 | $33.94M | +137.7% |
| 2020 | $14.28M | +446.6% |
| 2019 | $2.61M | +112.2% |
| 2018 | $1.23M | -30.6% |
| 2017 | $1.78M | -81.6% |
| 2016 | $9.64M | +818.2% |
| 2015 | $1.05M | -78.5% |
| 2014 | $4.89M | +709.4% |
| 2013 | $603.7K | +111.8% |
| 2012 | $285.0K | -72.5% |
| 2011 | $1.04M | +48.2% |
| 2010 | $700.5K | +21533.6% |
| 2003 | $3.2K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| November 30, 2025 | $4.98M | -76.6% | -46.6% |
| August 31, 2025 | $9.33M | -62.6% | -21.6% |
| May 31, 2025 | $11.90M | +282.7% | -27.4% |
| February 28, 2025 | $16.40M | +1068.1% | -23.1% |
| November 30, 2024 | $21.34M | +14413.6% | -14.4% |
| August 31, 2024 | $24.92M | +1125.2% | +701.3% |
| May 31, 2024 | $3.11M | +22.4% | +121.5% |
| February 29, 2024 | $1.40M | -72.5% | +855.1% |
- CytoDyn Inc. showed an increase of +282.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2003–2025 period, CytoDyn Inc.’s cash and equivalents has grown by 367503.5% (from $3.2 thousand to $11.90 million).
- The most recent figure is from CytoDyn Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 25, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: